Tower Research Capital (TRC)’s Liminal BioSciences Inc. Common Shares LMNL Stock Holding History

Tower Research Capital (TRC)’s Portfolio LMNL Stock Details LMNL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40	Closed	–	–	6554
2022 Q4	$0	Hold	40	–	–	﹤0.01%	6635
2022 Q3	$0	Hold	40	–	–	﹤0.01%	6728
2022 Q2	$0	Hold	40	–	–	﹤0.01%	6769
2022 Q1	$0	Hold	40	–	–	﹤0.01%	6825
2021 Q4	$0	Hold	40	–	–	﹤0.01%	6769
2021 Q3	$1K	Sell	40 -974	-96%	-$28.1K	﹤0.01%	5591
2021 Q2	$40K	Buy	1,014 +974	+2,435%	+$42.4K	﹤0.01%	3222
2021 Q1	$2K	Hold	40	–	–	﹤0.01%	5077
2020 Q4	$2K	Hold	40	–	–	﹤0.01%	4941
2020 Q3	$4K	Sell	40 -30	-43%	-$4.06K	﹤0.01%	4455
2020 Q2	$7K	Sell	70 -30	-30%	-$2.65K	﹤0.01%	4181
2020 Q1	$6K	Buy	100 +40	+67%	+$3.61K	﹤0.01%	2265
2019 Q4	$5K	Buy	+60	New	+$4.05K	﹤0.01%	2719

Other funds holding LMNL

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

ECM

Estabrook Capital Management New York $685M AUM 26.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Tower Research Capital (TRC)'s LMNL Position: Q1 2023 in Review

Tower Research Capital (TRC) sold out of Liminal BioSciences Inc. Common Shares (LMNL) in Q1 2023, closing a stake of 40 shares.

Tower Research Capital (TRC) first reported a position in LMNL in Q4 2019 and held it in 13 quarters. The position peaked at $40K in Q2 2021. 8 funds tracked by Wall St. Rank hold LMNL as of Q1 2023.

Tower Research Capital (TRC) reported no remaining Liminal BioSciences Inc. Common Shares position as of Q1 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 40 Liminal BioSciences Inc. Common Shares shares in Q1 2023.
Tower Research Capital (TRC) first reported a position in Liminal BioSciences Inc. Common Shares in Q4 2019 and held it in 13 quarters.
Tower Research Capital (TRC)'s Liminal BioSciences Inc. Common Shares position peaked at $40K in Q2 2021.
8 funds tracked by Wall St. Rank held Liminal BioSciences Inc. Common Shares as of Q1 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.